Newly Approved Drug for CLL: Acalabrutinib (Calquence)
View next
Published on November 21, 2019
The FDA has approved a new chronic lymphocytic leukemia drug: acalabrutinib (Calquence). Want to learn more about this newly approved drug? Watch our CLL video with expert Dr. William Wierda from MD Anderson Cancer Center to learn more about the treatment.
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.
What a wonderful time we had! We were excited like fans at a rock concert, but our rock stars were the medical experts.
